E99 Biomedical Special Roadshow on April 18 – Showcasing Innovative Healthcare Startups

Initiated by the E99 Medical & Health Investment Elite Alliance, this event features roadshow projects primarily in the biopharmaceutical sector. It aims to provide outstanding biopharmaceutical enterprises with expanded financing matchmaking channels, promote multi-party resource integration, and build a collaborative platform characterized by complementary strengths and mutual benefits.

April 18, 2019 (Thursday) 14:00-18:00

Conference Room, 11th Floor, Software Building, High-Tech Zone (No. 9 Gaoxin Zhongyi Road, Science and Technology Park, Nanshan District)

Investment Manager, Healthcare & Biomedical Sector

Shenzhen Beimei Pharmaceutical Co., Ltd. is a key enterprise supported by the Shenzhen Municipal Government, a high-tech enterprise in Shenzhen, a national technology-based small and medium-sized enterprise, and an enterprise included in the national high-tech enterprise cultivation database.

The company specializes in the field of pediatric prescription drugs, integrating research and development, licensing-in, and sales. In addition to its Shenzhen headquarters, it has a subsidiary in Jiangxi Province and a nationwide sales force. Leveraging precise product positioning, strategic planning, and execution, the company has achieved strong performance. Since launching nationwide operations, its compound annual growth rate (CAGR) over the past five years has reached 25.63%, with benchmark cities achieving a CAGR of 131.07%.

The Company has prioritized independent R&D and the introduction of overseas products as its core strategy, establishing specialized teams for R&D and overseas product acquisition. By continuously developing and introducing new varieties, it has steadily expanded its marketing, promotion, and sales networks, emerging as a leading enterprise in China’s pediatric pharmaceutical sector and creating greater value for us and our partners.

Shenzhen Puruijin Biopharmaceutical Co., Ltd. focuses on the research, development, and promotion of biologic drugs, having achieved phased R&D milestones. Its CAR-T CD19 and CAR-T BCMA products have been successfully applied in the last-line treatment of dozens of patients with relapsed or refractory leukemia, malignant lymphoma, multiple myeloma, and other conditions. The company’s first CAR-T cell therapy has submitted an Investigational New Drug (IND) application to the Center for Drug Evaluation (CDE). Other product pipelines targeting indications such as tumors and autoimmune diseases are developing in a tiered manner, backed by abundant reserve technologies, which bodes well for the company’s broad development prospects. Looking ahead, the company is committed to its mission of developing biologic drugs affordable to the Chinese population. Leveraging nanobodies—a cutting-edge international biotechnology platform—as its core, it will further strengthen original R&D, secure and own a portfolio of high-value international patents, and maintain and expand its leading advantage in the industry. While accelerating the market launch of CAR-T cell therapies, the company will promote the application and development of nanobodies in various fields, including bispecific and multispecific antibodies and in vitro diagnostics, striving to build a new biomedical industrial chain worth tens of billions of yuan. It aims to rank among the world’s top-tier biopharmaceutical companies.

Tianlan Biotechnology has established a leading domestic drug screening platform by leveraging its 39 years of research accumulation in the field of non-human primate (NHP) experimentation, its rare industry qualifications and licenses, and collaborations with world-class scientific teams. The company provides services such as R&D assistance, drug screening, and evaluation for global pharmaceutical enterprises, CROs, and academic research institutions. With industry-leading capabilities in disease model development and production scale, Tianlan Biotechnology’s models have been successfully applied to therapeutic research on various complex human diseases, including AIDS, Alzheimer’s disease, Parkinson’s disease, and diabetes. By utilizing its mature whole-genome sequencing and analysis capabilities for cynomolgus monkeys, the company continuously optimizes its R&D conditions for gene editing and cloning technologies. It is committed to achieving mass cloning of disease-model monkeys and applying them to a series of R&D and industrialization projects, including disease diagnosis, drug testing, and intervention.

Yiying Medical was established in 2018 and co-founded by several PhDs who returned to China after studying abroad. The founding team possesses extensive industry experience and profound technical expertise. Yiying Medical focuses on 3D CT imaging technology, aiming to enhance product performance with advanced imaging capabilities and provide high-quality services to customers.The company’s business scope covers CT equipment used in operating rooms, providing real-time intraoperative 3D image navigation to serve as the “super eyes” for surgical robots. It also involves robotic CT equipment, introducing the flexibility of robotics into medical imaging devices to replace the traditional model of “patients adapting to equipment” with “equipment adapting to patients,” thereby enabling standing-position CT imaging. Furthermore, its cardiac CT equipment achieves a temporal resolution of 10 ms, thoroughly resolving issues related to heart motion during traditional CT scans and making non-invasive early screening for cardiovascular diseases possible.To date, Yiying Medical has filed more than ten invention patents. Its first intraoperative CT device has completed registration testing and is expected to obtain the registration certificate by the end of the year. Clinical trials are currently being conducted in collaboration with clinical partner institutions. In 2018, the company won the Second Prize in the “Haizhi Cup” Entrepreneurship Competition organized by the Haimen Municipal Government, the Gold Award in the National Finals of the China “Internet+” College Student Innovation and Entrepreneurship Competition, and the Third Prize in the Jiangsu Province Innovation and Entrepreneurship Competition.

Changde Yungang Biotechnology Co., Ltd. was established in July 2003. It is a high-tech enterprise oriented towards exports, primarily engaged in the research, development, production, and sales of pharmaceutical intermediates. Its product portfolio includes a series of bile acids (such as ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, deoxycholic acid, and dehydrocholic acid) as well as various series of bile salts. In recent years, the company has consistently ranked second in China in terms of market share for ursodeoxycholic acid; this year, its market share reached 27%, representing an 8-percentage-point increase compared to 2017. The company has always specialized in the research, development, and production of biological extraction technologies and is the first and largest enterprise globally to industrially extract and produce ursodeoxycholic acid from duck gallbladders. The company holds nine invention patents, with three currently under review, and has multiple additional R&D technologies preparing for invention patent applications.

Jinchuang Biotech is a high-tech biotechnology company specializing in the research, development, and production of natural plant extracts. The company employs rigorously validated biotechnological methods to precisely extract bioactive compounds from plants. It provides functional ingredients to clients in the food and beverage, health supplement, cosmetic and daily chemical, and pharmaceutical industries. By drawing on global traditional practices in plant extraction production and integrating its own practical experience, Jinchuang Biotech has undertaken five years of continuous technological innovation in its manufacturing processes, achieving highly satisfactory results.

Litaike Technology was founded by a team of experts with nearly two decades of experience in rehabilitation assessment data diagnostics and rehabilitation robotics, both domestically and internationally. The company focuses on: (1) driving technological transformation in future data-driven rehabilitation assessment medicine (specifically in the cognitive and motor subfields), serving post-orthopedic surgery rehabilitation, quantitative neurological rehabilitation, and intelligent home-based rehabilitation; and (2) early diagnostic technologies for changes in brain function and behavior, providing product solutions for early screening and intervention for individuals with Alzheimer’s disease (dementia), brain functional impairments, and children with autism. Established three years ago, the company has prioritized the deployment of various modular hardware products for rehabilitation medicine, obtained five Class II medical device licenses, and achieved sales in the tens of millions. In the future, Litaike plans to establish a cross-regional, intelligent, modular home rehabilitation system based on its proprietary hardware core, along with remote rehabilitation assessment and auxiliary diagnostic services.

Zhiyao Tech was founded in 2017, with its headquarters in Shanghai and laboratories located in the Suzhou Industrial Park. As a company dedicated to developing artificial intelligence technologies that tangibly enhance drug discovery efficiency and address the challenges of new drug development through AI, Zhiyao Tech’s AI products under development cover all stages from Drug Discovery to Clinical Trial. By improving efficiency across each segment of the R&D process, the company aims to systematically and comprehensively increase the success rate of new drug development, thereby reducing R&D costs.

Zhiyao Technology has developed KangDock, a virtual drug screening and molecular docking tool. Its prediction accuracy (AUC) on test datasets has reached 93%, nearly 4 percentage points higher than AtomNet, a similar product from the U.S. unicorn company AtomWise.

Moore Biotech, established in 2008 as Wuhan Moore Biotechnology Co., Ltd., is China’s first high-tech enterprise dedicated to the development of bioactive peptide products. It features a 1,400-square-meter GMP-compliant laboratory and a cosmetics production workshop.
More Biotech has constructed the world’s most comprehensive gene library of bioactive peptides derived from medicinal wild scorpions. The company has also established the world’s first industrial-scale genetic engineering platform for polypeptides containing multiple disulfide bonds, thereby creating an integrated technological platform for the screening, design, identification, and production of therapeutic peptides.

Moore Biotech has achieved a series of original, internationally leading breakthroughs in the field of peptides, making significant progress in the development of novel peptide-based drugs (including classified military and special-purpose pharmaceuticals). The company also applies its proprietary innovative technologies to the development of health products, such as functional skincare products, establishing itself as a key innovation hub in China for the creation of novel peptide drugs and health products.

Shenzhen Capital Group, GTJA Capital, Sharing Investment, Aoyin Capital, Qingcheng Capital, Touhu.com, VCBeat, GF Securities, BGI Win-Win, Cornerstone Investments, Oriental Fortune Capital, Cowin Capital, Leaguer Venture Capital, Qianhai Wutong, Zhongnan Venture Capital, Duoshu Capital, Rongyu Capital, Hechuang Capital, Zhongli Capital, Ruixiangyuan Fund, Xin Heng Lida, Guoke Jiahe, Pengnian Venture Capital, Yinxing Group, Longteng Investment...

Note: For the Biomedical Special Session Roadshow on April 18, representatives from the aforementioned institutions will be invited by specific invitation. Other industry peers may attend only upon recommendation by these invited representatives. All attendees must register by scanning the QR code below; walk-in registrations will not be accepted.

Scan the QR Code to Register

Elite Alliance for Healthcare Investment (E99), jointly initiated by Qingcheng Capital, Touhu.com, and VCBeat, gathers top-tier healthcare investment professionals and attracts high-quality healthcare projects to build an influential healthcare financing and investment roadshow platform. “Aggregating elite strengths to create future value.” Outstanding roadshow projects stem from in-depth analysis and evaluation by investment managers, facilitating efficient investment and financing exchanges among alliance members and achieving a win-win outcome for both project sponsors and investors.